Empowered Patient Podcast

Karen Jagoda
undefined
Aug 18, 2026 • 23min

Virtual Transitionist Model Reduces Complications after Acute Care Events with Dr. David Feldman Dimer Health

Dr. David Feldman is the Chief Medical Officer at Dimer Health, a virtual care medical practice designed to improve patient outcomes during the critical 1-3 days following hospital discharge, outpatient surgery, or emergency room visits. The company addresses the gap in post-acute care between hospital care and primary care follow-up by proactive monitoring, medication management, and pain control. Inspired by the hospitalist model, Dimer is defining a transitionist model that is tailored to each patient's needs and home environment, intervening early on minor complications to reduce emergency room revisits and hospital readmissions. David explains, "Dimer Health is a health tech company. It's a medical practice deliberately built to better serve patients after any post-acute care event. And what I mean by that is patients go to the emergency room and are discharged, patients are admitted to the hospital and are discharged, maybe they have surgery. And it's in those first 1 to 3 days after that when the trajectory of their recovery is really determined. As an emergency room physician, I see a lot of those complications that come in. A couple of our founders were also emergency room providers, and so we wanted to be deliberate about building a medical practice, a virtual care medical practice that fits right into that window to prevent those patients from coming back to the hospital." "And I think a good example of that is a very realistic scenario: a patient has joint replacement surgery, and it's a couple of days later. Their pain medications are changing. Maybe they're transitioning to different types of pain medications, or they're just starting to utilize their pain medications. They're adjusting to new mobility issues. Maybe they're learning different kinds of injections or blood thinners. They're not sleeping well. Families are trying to help, and there are just changes to their home life that occur because of the procedure that happened. And when you're outside the four walls of the hospital, it's sometimes difficult to understand what's normal post-op healing and what's more concerning than that." #DimerHealth #JointReplacement, #PostAcuteCare, #PatientSafety #HospitalReadmissions, #PostDischargeCare, #SurgicalRecovery dimerhealth.com Download the transcript here
undefined
Aug 17, 2026 • 17min

Certified Drug Label Translations in 26 Languages for Limited English Proficient Patients with Sharon Blank RxTran

Sharon Blank, CEO of RxTran, highlights the value of certified translations of prescription dosing instructions in 26 languages to ensure that limited-English-proficient patients can understand dosing and medication risks. The organization works with pharmacies to deliver translations created by native-speaking pharmacists rather than by automated systems or untrained interpreters. As this LEP population grows, RxTran advocates for standardized, human-verified translation practices to ensure healthcare access and patient safety across all populations. Sharon explains, "So RxTran's mission is to provide certified translation of the dosing instructions on prescription labels and ensure that LEP patients have the ability to understand their dosing instructions. And our primary clients include both small individual pharmacies as well as large chains." "Truthfully, everybody needs the exact same standard of care, whether you are proficient in English or not. And we always say that good enough is not good enough. So it is our belief that you absolutely must have the translated SIGS be done by a pharmacist who is native in the language into which it's being translated. And then be stored in a bank. So it's not pre-written text dosing instructions. It is from a data bank of certified translations." "So, right now, there are sort of three real issues in that situation. And the dangerous outcomes include the patient won't take the medication because they're fearful. Or they take the wrong dose or at the wrong time. And what we hear time and time again is that they rely on an untrained relative, neighbor, or friend to translate. And all of these just really potentially cause great harm." #RxTran #PatientSafety #HealthEquity #Pharmacy #LimitedEnglishProficiency #LEPpatients #MedicationSafety #LanguageAccess #HealthcareInnovation #PatientAdvocacy #HealthcareInnovation #EmpoweredPatient #MedicationAdherence #PharmacyInnovation #WomenInHealthTech #HealthTech RxTran.com Download the transcript here
undefined
Aug 13, 2026 • 16min

Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki

Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. Craig explains, "Worki is solving the fragmentation tax that is plaguing the HR and workforce components of the healthcare industry. And when I say the fragmentation tax, what I'm talking about is that within healthcare, there are a number of legacy systems and non-legacy systems, meaning just spreadsheets and pieces of paper that are part of the HR workforce picture. These are leading to what I call visibility gaps or blind spots, as well as high administrative friction or burden for frontline clinical workers." "So the ability to manage the workers, the ability to engage them, the ability to efficiently deploy AI in a meaningful way through a combination of data, has been hampered. And what we do is we solve for that by unifying that fragmented information and then putting it into action around key HR workforce roles. Specifically, we start with usually access scheduling roles as well as career amplification roles." "What I mean by clear career amplification could be retention, could be upskilling in the face of the evolution of work around how AI is impacting their tasks associated with their roles. We're basically helping organizations, particularly healthcare organizations, address these fundamental fragmentation issues and then activate in a way that empowers HR to solve for the evolution of work." #Worki #HealthcareWorkforce #AIinHealthcare #WorkforceInnovation #HealthcareOperations #HealthcareTechnology #FutureOfHealthcare #Healthcare #Nursing #HealthcareHR #WorkforceManagement #HealthIT #Staffing #Upskilling #PatientCare #DigitalTransformation worki.us Download the transcript here
undefined
Aug 12, 2026 • 24min

Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health

Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an integrated care company that exists to treat the most complex mentally ill. So those that are suffering from schizophrenia, bipolar disorder, major depressive disorder. And we do so through these community-oriented clinics that deliver comprehensive care that's psychiatry-led, but also incorporates therapy, primary care, social services, peer support specialists, dieticians for a lot of nutrition guidance, and health coaching. Then clinic care coordinators manage all the in-between things that need to happen to get somebody back on track and living a healthy, stable life." "Another core pillar within the company that I'll just add is getting into technical research and innovation, with lots of work we can do to uncover what is causing this, what interventions we can deploy. How can we partner with others in the ecosystem, whether that's pharma or life sciences, to advance psychiatric care and see if we can get towards putting many of these conditions into remission?" #AmaeHealth #MentalHealthCare #SevereMentalIllness #IntegratedCare #MetabolicPsychiatry #Schizophrenia #BipolarDisorder #ValueBasedCare #ContinuityOfCare #HealthcareInnovation #Psychiatry amaehealth.com Download the transcript here
undefined
Aug 11, 2026 • 19min

Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO

Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop technologies that allow our clinicians to preserve, assess, and transport organs. So, in doing so, we're able to be part of the solution by helping increase the number of organs available for transplantation. In my role at XVIVO, I get to work closely with clinical teams and partners to support the implementation of our technologies and their programs, not only in the US but around the world. So really everything that we do is centered around helping more patients receive those lifesaving transplants." "So this collaboration is so incredibly important, not only for XVIVO. I think for the transplant community as a whole, it brings advanced lung assessment directly into the organ recovery process. XVIVO lung perfusion- you'll hear me say EVLP. It is placed into the workflow at the organ procurement organization level rather than in a separate step later in transplantation." "So Indiana Donor Network, I'll call it IDN, is the first organ recovery organization in the US that has an in-house lung perfusion program. And through this partnership, IDN can assess donor lungs using EVLP before transplantation decisions are finalized. So for us, it does matter for a few reasons. And I think it's important to emphasize that two in 10 lungs are transplanted, which means that 80% of them are declined." #XVIVO #OrganTransplantation #HealthcareInnovation #MedTech #PatientOutcomes #TransplantMedicine #LungTransplant #EVLP #OrganDonation #TransplantInnovation #IndianaDonorNetwork #PerfusionSolution #HealthcareInnovation #OPO #PatientCare XVIVOgroup.com Download the transcript here
undefined
Aug 10, 2026 • 22min

Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI

Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI innovator category, and we're applying our proprietary platform to the challenges that exist in the world of drug development for pharmaceutical and biotech companies. Primarily our focus is on the first and the last stage of that process. So the first stage is what you call drug target discovery. So when you take a medication, it targets something in your body. So we're trying to identify novel targets that we believe are the root cause of certain diseases. And then we are also focused on the final stage, which is phase three clinical trials. That's where we have our experience. And that's obviously a very critical and pivotal point in the process and the final stage of a long 10- to 15-year, one- to two-billion-dollar drug development process." "You need to have the right tool for a certain problem and then data, and they go together. I think on the data side, getting access to rich, deep data sets is critical. And fortunately, the cost to generate that type of data has come down pretty significantly over the past, say, 10 years. So now, for example, we have a project where we have brain data, and it's the type of data where you can really make discoveries and insights and so forth. And so that's a really critical part of this process. The other part is: what tool do you have, and what problem are you trying to solve? Our technology is unique. I'd say most companies use technology that comes from NVIDIA and AWS. So they're all kind of using the same tools from the same toolbox." "Our technology comes from Johns Hopkins University Applied Physics Lab, which is a world-renowned institution. We have IP around our platform, and we've continued to innovate over the years. It definitely has unique capabilities, and it is specifically designed for the types of problems that exist in drug development." #BullFrogAI $BFRG, #AI, #AIinBiotech, #MachineLearning, #DrugDevelopment #AIinHealthcare #PrecisionMedicine #Neuropsychiatry #Oncology #DigitalHealth #ClinicalTrials #Biomarkers #bfLEAP bullfrogai.com Download the transcript here
undefined
Aug 10, 2026 • 20min

Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS

Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver real-time insights. Greg explains, "We're a data-first company that is focused on improving healthcare outcomes for underserved communities. That's pretty broad. But if you think about traditional healthcare, especially in the United States, if you look at 20% of patients or individuals driving about 80% of costs in healthcare. And traditional healthcare has not been able to really put a dent in this over time. And really the reason is that traditional healthcare has not addressed the true drivers of people's health, especially in underserved communities." "Traditional healthcare has not done a good job of addressing those non-clinical issues, and it's done an even worse job of orchestrating and ensuring that across all those dimensions, we're addressing people's health. And so, in terms of the mission, it's about breaking down the silos in people's care and in the data available to those who support them. Making sure we're looking at all dimensions of people's health and helping them navigate to live happier, healthier lives, especially for communities facing many of the challenges I've mentioned." #ClinNEXUS #HealthcareInnovation #PopulationHealth #SocialDriversOfHealth #CareCoordination #AIinHealthcare #Medicaid #ValueBasedCare clinNexus.com Download the transcript here
undefined
Aug 6, 2026 • 22min

Image-Based Digital Biomarkers Detected by AI Platform to Transform Drug Development and Clinical Care with Susan Wood VIDA

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Download the transcript here
undefined
Aug 5, 2026 • 20min

Clinician-Supervised Purpose-Built AI Bridges Behavioral Health Therapy Gaps with Luis Voloch Jimini Health

Luis Voloch, Co-Founder and CEO of Jimini Health, focuses on mental health through the Sage platform, which provides continuous AI support for patients while keeping clinicians informed and in control. The approach addresses the problem of patients turning to general-purpose AI for behavioral health support by offering a HIPAA-compliant, purpose-built alternative with proper safeguards and clinician supervision. The platform improves patient adherence to therapy and provides valuable information about progress between appointments, which is particularly important in mental health care where outcomes are non-linear and diagnostic precision is limited. Luis explains, "Right now, the AI healthcare environment is, I'd say, largely split when it comes to clinical AI between largely clinician-facing and back-office capabilities. So things like AI scribes and RCM tools and clinician coaching tools and products like that on one hand, with on the other hand, things that are primarily for patients. You may see things on the app store that are like AI therapists or products that are standalone for patients. And where Jimini stands is really as unifying both of these, where the core thesis for the company is that the right way to help patients and to build helpful clinical AI products is by integrating with the clinician as well, where the clinician has the ability to oversee what the AI is doing and to guide what the AI is doing." "The company's belief is that we need to build purpose-built AIs for mental health that are HIPAA-compliant and safe, with all the right guardrails. And most importantly, where clinicians are in the loop and where the clinicians can oversee and guide what the AI is doing." "We primarily work with large behavioral health provider organizations interested in improving the quality of care they deliver. One specific big opportunity we bring is bridging the time between sessions so that patients have additional support. The core of the product is what we call Sage. Sage is an app that engages with patients in various ways, with the guidance of the clinician, so that Sage knows what is happening in the therapy sessions or whatever other appointments the patient is having. It is then able to follow the clinical priorities of the clinician when the clinician is not there, and Sage supports these patients on a daily basis." #JiminiHealth #MentalHealth #DigitalHealth #BehavioralHealth #AIinHealthcare #PatientEngagement #CareAdherence #Telehealth #HealthTech #AI #MentalHealth #PatientSafety jiminihealth.com Download the transcript here
undefined
Aug 5, 2026 • 22min

Localized Immunotherapy by Direct Injection Treats Solid Tumors and Activates the Immune System with Lew Bender Intensity Therapeutics

Lew Bender, Founder and CEO of Intensity Therapeutics, has developed a novel approach to treating solid tumors through direct intratumoral injection of existing chemotherapy drugs. The company uses a proprietary formulation containing a special molecule that makes water-based drugs soluble in fatty tissue, allowing cisplatin and vinblastine to penetrate tumor cells effectively. Beyond direct killing of cancer cells, the approach triggers an immunological response that trains the immune system to recognize and attack cancer cells throughout the body, including metastatic tumors that were not directly injected. Lew explains, "We're injecting directly into the tumors, and we have identified a formulation that allows for water-based drugs to become soluble in fat and water. Effectively, a tumor is fat and water. And while it has been tried before to inject water into fat, I helped to develop a chemistry that allows for water-based products to be absorbed by fatty tissue like tumors." "We are injecting our formulation, which is a special molecule called SHAO, that makes things soluble in fat and water, and two very well-known potent anti-cancer agents, cisplatin and vinblastine, that are able to kill cancers when they get into the cancer cells. So we dose based on the size of the tumor, check into the tumors, and the tumors in an immunological way. So what does that mean? It means that as the tumor cells die, they create chemicals that allow for the influx and recognition of the immune cells that this is not a good entity to be in the body." "We are killing the cancer with the drug, but at the same time training the immune system on the tumors so that the immune system can recognize the cancer as not self and attack the cancer in a more precise way." #IntensityTherapeutics $INTS #CancerResearch #Oncology #Biotech #CancerCare #ClinicalTrials #BreastCancer #TargetedOncology #IntratumoralInjection #OncologyInnovation #ImmunoOncology #IntratumoralTherapy #SolidTumors #TNBC #Sarcoma #HealthcareProfessionals intensitytherapeutics.com Download the transcript here

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app